Oberweis Asset Management Inc. Invests $6.54 Million in Blueprint Medicines Co. (NASDAQ:BPMC)

Oberweis Asset Management Inc. acquired a new position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 75,000 shares of the biotechnology company's stock, valued at approximately $6,542,000. Oberweis Asset Management Inc. owned approximately 0.12% of Blueprint Medicines at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Torray Investment Partners LLC boosted its stake in Blueprint Medicines by 1.1% during the fourth quarter. Torray Investment Partners LLC now owns 16,499 shares of the biotechnology company's stock worth $1,439,000 after buying an additional 186 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Blueprint Medicines by 0.7% during the 3rd quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company's stock valued at $3,259,000 after acquiring an additional 265 shares in the last quarter. Summit Investment Advisors Inc. increased its stake in Blueprint Medicines by 4.4% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,652 shares of the biotechnology company's stock valued at $580,000 after acquiring an additional 283 shares during the period. Pitcairn Co. raised its position in Blueprint Medicines by 2.8% in the fourth quarter. Pitcairn Co. now owns 10,608 shares of the biotechnology company's stock worth $925,000 after purchasing an additional 293 shares in the last quarter. Finally, Hillsdale Investment Management Inc. boosted its holdings in Blueprint Medicines by 0.6% during the fourth quarter. Hillsdale Investment Management Inc. now owns 50,830 shares of the biotechnology company's stock valued at $4,433,000 after purchasing an additional 310 shares in the last quarter.

Insider Activity at Blueprint Medicines

In other news, insider Ariel Hurley sold 3,203 shares of Blueprint Medicines stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $92.62, for a total transaction of $296,661.86. Following the transaction, the insider now directly owns 18,270 shares of the company's stock, valued at $1,692,167.40. This trade represents a 14.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Christina Rossi sold 2,274 shares of the business's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $95.02, for a total transaction of $216,075.48. Following the completion of the transaction, the chief operating officer now directly owns 69,266 shares of the company's stock, valued at $6,581,655.32. This trade represents a 3.18 % decrease in their position. The disclosure for this sale can be found here. 4.21% of the stock is currently owned by corporate insiders.

Blueprint Medicines Trading Up 0.1 %

BPMC traded up $0.12 during trading on Wednesday, reaching $88.60. 333,686 shares of the company's stock were exchanged, compared to its average volume of 768,212. The company's fifty day moving average price is $87.34 and its 200-day moving average price is $93.15. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. The firm has a market capitalization of $5.66 billion, a PE ratio of -82.04 and a beta of 0.75. Blueprint Medicines Co. has a fifty-two week low of $73.04 and a fifty-two week high of $121.90.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. As a group, equities analysts forecast that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently commented on BPMC. Stephens restated an "overweight" rating and set a $140.00 target price on shares of Blueprint Medicines in a research report on Thursday, January 2nd. Wolfe Research started coverage on shares of Blueprint Medicines in a research note on Tuesday, March 18th. They issued an "outperform" rating on the stock. Piper Sandler increased their target price on shares of Blueprint Medicines from $109.00 to $119.00 and gave the stock a "neutral" rating in a research report on Monday, January 27th. HC Wainwright restated a "buy" rating and issued a $135.00 price target on shares of Blueprint Medicines in a research report on Friday, February 14th. Finally, Wedbush reaffirmed an "outperform" rating and set a $128.00 price objective on shares of Blueprint Medicines in a report on Wednesday, April 16th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $124.53.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.